The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
You may also be interested in...
Medical device and diagnostic companies are developing innovative new products for women with breast cancer designed to facilitate earlier diagnosis, improve diagnostic accuracy, increase surgical precision, and enable the least invasive, most breast-conserving approach to breast cancer surgery. With the number of breast cancer cases in the US projected to increase dramatically by 2030, the success of these technologies depends on their ability to improve cosmetic results and survival rates while lowering overall health care costs.
With the breast cancer screening population expected to reach almost 250 million by 2018, TiaLinx says its new AR60-A scanner is the first non-contact, high-resolution imaging technology that does not emit ionizing radiation, and is an affordable screening alternative for the 210,000 primary care physicians in the US and significantly more worldwide.
GE Healthcare launched in June the Invenia Automated Breast Ultrasound System (ABUS), the first FDA-approved breast cancer screening option for women with dense breasts.